Current research status on immune-related adverse events / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
;
(12): 271-276, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-936075
ABSTRACT
Immune checkpoint inhibitors have progressed rapidly over the past decade and have become one of the most promising oncology treatments. However, immune checkpoint inhibitors reduce T-cell tolerance and lead to a unique spectrum of immune-related adverse events (IRAE). IRAE can involve multiple systems, including endocrine, gastrointestinal, respiratory and skin systems and there is no predictive marker with high specificity and sensitivity. Mild IRAE can be alleviated by discontinuing immune checkpoint inhibitors while severe IRAEs require active intervention. The first-line treatment is glucocorticoids, and immunosuppressants can be considered in refractory cases. However the optimal choice of immunosuppressants is currently controversial. This review provides an overview of the epidemiology and possible mechanisms of immune-related adverse events, outlines some promising predictive biomarkers, and describes several immunotherapy-related organ toxicity and management.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Factores Inmunológicos
/
Inmunosupresores
/
Inmunoterapia
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Gastrointestinal Surgery
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS